| Patent application number | Description | Published |
|---|
| 20090081649 | Diagnostic method for detecting cancer by measuring amount of cytokine like il -6 - The present invention relates to a diagnostic method for predicting the possible recurrence of tumours in cancer patients. The method comprises culturing blood cells from a patient suffering from cancer in the presence of a cytokine stimulating factor, where after the amount of induced cytokine thereby produced is determined giving an indication of the risk of recurrence of the cancer. | 03-26-2009 |
| 20100311078 | IMMUNOREGULATION IN CANCER, CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES - The present invention primarily relates to a method for analyzing the amount of immunoregulatory integrin binding factors and/or patient endogenous antibodies which are directed against such factors, the factors having the capacity to modulate the immune functions in a subject suffering from cancer or inflammatory or autoimmune diseases, by utilizing binding reagents to determine these factors and/or the patient endogenous antibodies which are directed against such factors, whereby the prognosis and/or the therapeutic efficacy of any treatment of a subject suffering from cancer or inflammatory or autoimmune diseases can be determined and/or monitored. The invention further relates to the use of therapeutically active compounds for eliminating, inhibiting or enhancing such binding factors for the manufacture of pharmaceuticals to be used in the treatment of cancer, inflammatory conditions or autoimmune diseases. | 12-09-2010 |
| 20100323370 | METHOD FOR DETERMINING IMMUNE SYSTEM AFFECTING COMPOUNDS - The present invention relates to a method for increasing efficacy and/or possibility of therapeutic treatment of cancer, wherein any dys-regulatory mechanism, including inducing factor/s, of the production of immunoregulatory substances, including one or more cytokines, including IL-1β, IL-1Ra, IL-6, IL-10, IL-17, TNF-α, and others, is therapeutically controlled to minimise pathological production of such immunoregulatory substances, to enhance the therapeutic control of a malignant tumour in a subject suffering from a cancer, a method for analysing dys-regulatory mechanism controlling substances, kit for such analysis, use of certain compounds for preparing pharmaceutical preparations, and pharmaceutical preparations. | 12-23-2010 |
| 20110262470 | IMMUNOREGULATORY STRUCTURES FROM NORMALLY OCCURRING PROTEINS - The present invention relates to isolated protein sequences that correspond to cell binding peptides, fragments, neo-structures and/or neo-epitopes of a normally occurring serum protein present in human tissue, wherein the peptide, fragment, neo-structure and/or neo-epitope has an immunoregulatory activity and is the result of either an enhanced proteolytic activity and/or conformational changes in a tissue, or a malignant tumour. In the present patent application, a common structure of several of these peptides, fragments, neo-structures and/or neo-epitopes, having immunoregulatory activity by binding to receptors on immune cells, has been identified. The present invention further also relates to monoclonal and/or polyclonal antibodies directed to a cell binding fragment of a normally occurring serum protein present in human tissue, as described above. | 10-27-2011 |
| 20110287969 | IMMUNOREGULATION IN CANCER, CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES - The present invention primarily relates to a method for analyzing the amount of immunoregulatory integrin binding factors and/or patient endogenous antibodies which are directed against such factors, the factors having the capacity to modulate the immune functions in a. subject suffering from cancer or inflammatory or autoimmune diseases, by utilizing binding reagents to determine these factors and/or the patient endogenous antibodies which are directed against such factors, whereby the prognosis and/or the therapeutic efficacy of any treatment of a subject suffering from cancer or inflammatory or autoimmune diseases can be determined and/or monitored. The invention further relates to the use of therapeutically active compounds for eliminating, inhibiting or enhancing such binding factors for the manufacture of pharmaceuticals to be used in the treatment of cancer, inflammatory conditions or autoimmune diseases. | 11-24-2011 |
| Patent application number | Description | Published |
|---|
| 20090208562 | Vaccine Composition Comprising a Fibronectin Binding Protein or a Fibronectin Binding Peptide - The present invention relates to a composition comprising at least one fibronectin binding protein, and/or at least one a truncated fibronectin binding protein and/or at least one fibronectin binding peptide, all comprising at least one fibronectin binding domain; and at least one Iscom matrixcomplex and/or liposome and/or at least one lipid and at least one saponin, whereby the at least one lipid and the at least one saponin may be in complex, solution or suspension. Further, it regards use thereof for the production of a vaccine against a micro organism that comprises at least one one fibronectin binding domain. It also regards a kit of parts comprising at least two compartments, wherein one compartment comprises at least one truncated fibronectin binding protein and/or a fibronectin binding peptide, that comprises at least one fibronectin binding domain, and another compartment comprises an instruction for use and/or an Iscom matrixcomplex and/or an iscom complex and or a liposome. Further it relates to a method for vaccination of an individual. | 08-20-2009 |
| 20110303563 | VACCINE COMPOSITION COMPRISING A FIBRONECTIN BINDING PROTEIN OR A FIBRONECTIN BINDING PEPTIDE - The present invention relates to a composition comprising at least one fibronectin binding protein, and/or at least one a truncated fibronectin binding protein and/or at least one fibronectin binding peptide, all comprising at least one fibronectin binding domain; and at least one iscom matrix complex and/or liposome and/or at least one lipid and at least one saponin, whereby the at least one lipid and the at least one saponin may be in complex, solution or suspension. Further, it regards use thereof for the preparation of a vaccine against a micro organism that comprises at least one fibronectin binding domain. It also relates to a kit of parts comprising at least two compartments, wherein one compartment comprises at least one truncated fibronectin binding protein and/or a fibronectin binding peptide, that comprises at least one fibronectin binding domain, and another compartment comprises an instruction for use and/or an iscom matrix complex and/or an iscom complex and or a liposome. Further it relates to a method for vaccination of an individual. | 12-15-2011 |
| Patent application number | Description | Published |
|---|
| 20090124989 | Absorbent Articles Comprising Acidic Superabsorber and an Organic Zinc Salt - An absorbent article, such as a diaper, panty diaper, sanitary napkin or incontinence device including a liquid-permeable topsheet, a liquid-impermeable backsheet and an absorbent core enclosed between said liquid-permeable topsheet and said liquid-impermeable backsheet, wherein the absorbent core includes a superabsorbent material, wherein the superabsorbent material is an acidic superabsorbent material having a pH of 5.5 or less measured, for example, using test EDANA WSP 200.2 and the absorbent core additionally includes an organic zinc salt, in particular zinc ricinoleate. The combination of organic zinc salt and acidic superabsorber exerts a synergistic effect in the suppression of basic malodours, such as ammonia. | 05-14-2009 |
| 20100047303 | ABSORBENT ARTICLES COMPRISING AN ORGANIC ZINC SALT AND AN ANTI-BACTERIAL AGENT OR ALKALI METAL CHLORIDE OR ALKALINE EARTH METAL CHLORIDE - An absorbent article, such as a diaper, panty diaper, sanitary napkin or incontinence device includes a topsheet, a backsheet and an absorbent core enclosed between the topsheet and the backsheet. The absorbent core includes an anti-bacterial agent or an alkali metal or alkaline earth metal chloride in combination with an organic zinc salt, in particular, zinc ricinoleate. The combination of antibacterial or (earth) alkali metal chloride and organic zinc salt exerts a synergetic effect in the suppression of malodours, such as ammonia. | 02-25-2010 |
